[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352338-105":59,"doc-detail-352338-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","digital-biomarkers-for-precision-early-detection-of-lung-cancer-integrating-ai-driven-multi-omics-into-clinical-pathways","Digital Biomarkers for Precision Early Detection of Lung Cancer: Integrating AI-Driven Multi-Omics Into Clinical Pathways","","Lung cancer drives the highest cancer-related mortality worldwide, making earlier detection across real-world screening and patient management pathways an urgent clinical need. Advances in multi-omics enable biomarker discovery for early-stage disease, especially in high-risk monitored populations. This review evaluates early diagnostic biomarkers across genomics, epigenomics, transcriptomics, proteomics, metabolomics and microbiomics, and summarizes how AI—machine learning and deep learning—integrates multi-omics to support clinical decision-making. It also assesses utility in risk stratification and clinical workflow alignment while addressing translation barriers.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/digital-biomarkers-for-precision-early-detection-of-lung-cancer-integrating-ai-driven-multi-omics-into-clinical-pathways/352338/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/digital-biomarkers-for-precision-early-detection-of-lung-cancer-integrating-ai-driven-multi-omics-into-clinical-pathways/352338.png","ImageObject",300,407,{"name":92,"@type":93},"Aria","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",15,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What problem does the review focus on in lung cancer care?","Question",{"text":113,"@type":114},"The review addresses the lack of robust early detection tools and the need for biomarkers that can support real-world screening and patient management pathways.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which omics layers and approaches are covered in the review?",{"text":118,"@type":114},"It evaluates biomarkers across genomics, epigenomics, transcriptomics, proteomics, metabolomics, and microbiomics, and discusses AI methods including machine learning and deep learning to integrate multi-omics datasets.",{"name":120,"@type":111,"acceptedAnswer":121},"What clinical benefits are expected from AI-driven multi-omics biomarkers?",{"text":122,"@type":114},"The review highlights improved risk stratification, diagnostic refinement, histological subtyping, and support for treatment planning, including potential incorporation into screening algorithms and CDSS.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},352338,1790265482,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},2336464648322,"https://ap-avatar.wpscdn.com/avatar/2200025388227c56fec?_k=1778556882303663488","Cancer Medicine  \n|  REVIEW  OPEN ACCESS \u003Cbr>Digital Biomarkers for Precision Early Detection of Lung Cancer: Integrating AI-Driven Multi-Omics Into Clinical Pathways\u003Cbr>Fan Bu1,2  | Zhi-Qiang Ling1,2 \u003Cbr>1Zhejiang Cancer Institute, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China | 2The Second Clinical Medical College of Zhejiang Chinese Medicine University, Hangzhou, People's Republic of China\u003Cbr>Correspondence: Zhi-Qiang Ling ([lingzq@zjcc.org.cn](lingzq@zjcc.org.cn))\u003Cbr>Received: 25 October 2025 | Revised: 21 December 2025 | Accepted: 19 January 2026\u003Cbr>Keywords: artificial intelligence | early detection | liquid biopsy | lung cancer | multi-omics | translational biomarkers |\n| --- |\n| ABSTRACT\u003Cbr>Background: Lung cancer remains the leading cause of cancer-related mortality worldwide, highlighting the urgent need for earlier detection within real-world screening and patient management pathways. Recent advances in multi-omics technologies have created new opportunities for identifying biomarkers associated with early-stage lung cancer, particularly in high-risk populations under clinical surveillance.\u003Cbr>Methods: This review systematically evaluates early diagnostic biomarkers across multiple omics layers, including genomics, epigenomics, transcriptomics, proteomics, metabolomics and microbiomics. It also summarises the application of artificial intelligence (AI), particularly machine learning and deep learning approaches, for integrating and analysing complex multi-omics datasets to support biomarker discovery and clinical decision-making.\u003Cbr>Results: Multi-omics strategies are accelerating the identification of molecular signatures relevant to early lung cancer detection. AI-driven methods enable the extraction of latent patterns from high-dimensional data, facilitating risk stratification, diagnostic refinement, histological subtyping and treatment planning. The review highlights the clinical utility of these biomarkers and their potential incorporation into screening algorithms, as well as the development of AI-based clinical decision support systems (CDSS) aligned with real-world clinical workflows. However, major barriers to clinical translation remain, including multi-centre data heterogeneity, limited model interpretability affecting clinical trust, regulatory and cost-effectiveness challenges and insufficient validation in prospective cohorts. |\n|  |\n| Abbreviations: A1AT, alpha-1-antitrypsin; AUC, area under the curve; BAL, bronchoalveolar lavage; CA125, cancer antigen 125; CDSS, clinical decision support system; CE, cholesteryl ester; CEA, carcinoembryonic antigen; cfRNA, cell-free RNA; CgA, chromogranin A; CGI, CpG Island; CIS, carcinoma in situ; CNV, copy number variation; CT, computed tomography; ctDNA, circulating tumour DNA; CTSD, cathepsin D; CYFRA 21-1, cytokeratin-19 fragment; ddPCR, Droplet Digital Polymerase Chain Reaction; DL, deep learning; DNMT, DNA methyltransferase; DNN, deep neural network; EGFR, epidermal growth factor receptor; EHR, electronic health record; FTICR-MS, Fourier Transform Ion Cyclotron Resonance Mass Spectrometry; GAS5, growth arrest-specific 5; GlcNAc, N-acetylglucosamine; H&E, haematoxylin and eosin; HE4, human epididymis protein 4; HER, human epidermal growth factor receptor; HSP60, heat shock protein 60; IRB, Institutional Review Board; KL Divergence, Kullback–Leibler divergence; LC–MS, liquid chromatography–mass spectrometry; LDCT, low-dose computed tomography; lncRNA, long non-coding RNA; LPC, lysophosphatidylcholine; LPE, lysophosphatidylethanolamine; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; miRNA, microRNA; ML, machine learning; MRM, multiple reaction monitoring; MSI, microsatellite instability; MSP, methylation-specific PCR; ncRNA, non-coding RNA; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer; NSE, neuron-specific enolase; OMICS, comprehensive molecular profiling (genomics, transcriptomics, etc.); OTU, operational taxonomic uni","cbCaijwC164zSNph","https://ap.wps.com/l/cbCaijwC164zSNph","pdf",1554299,18,"English","# Abstract\n## Background\n## Methods\n## Results\n# Abbreviations\n# Introduction\n## Lung cancer burden and screening limitations\n# Conclusions","[{\"question\":\"What problem does the review focus on in lung cancer care?\",\"answer\":\"The review addresses the lack of robust early detection tools and the need for biomarkers that can support real-world screening and patient management pathways.\"},{\"question\":\"Which omics layers and approaches are covered in the review?\",\"answer\":\"It evaluates biomarkers across genomics, epigenomics, transcriptomics, proteomics, metabolomics, and microbiomics, and discusses AI methods including machine learning and deep learning to integrate multi-omics datasets.\"},{\"question\":\"What clinical benefits are expected from AI-driven multi-omics biomarkers?\",\"answer\":\"The review highlights improved risk stratification, diagnostic refinement, histological subtyping, and support for treatment planning, including potential incorporation into screening algorithms and CDSS.\"}]","Digital Biomarkers for Precision Early Detection of Lung Cancer: Integrating AI-Driven Multi-Omics Into Clinical Pathways | PDF",1790099046,45,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/25bcb4558cb43202d25a71552d5bb6bc.webp",983,1291,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a78effbb393ff2359e59eb8fd66ce8b.webp",982,1290,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9cbd4700c368b166b453c8e1f16e1ab8.webp",981,1289,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d00419959fe1aed2762588d9620e99fa.webp",980,1287]